Pfizer’s research and development engine is positioned to offset patent expirations on established blockbusters. Late-stage trials for the investigational oncology asset PF-4404 are enrolling over 1,200 patients across three indications, with topline data expected in H2 2026. In parallel, the acquisition-sourced weight-management candidate MET-097i has cleared mid-stage endpoints for mean body-weight reduction of 12.3% at 24 weeks versus placebo, supporting a pivotal trial slated to commence in Q3. Management projects that approvals for these two candidates alone could add an incremental $4.5 billion in annual revenues by 2029, helping restore Pfizer’s organic growth after three consecutive years of revenue declines.

In October 2025, Pfizer secured a three-year exemption from import duties on active pharmaceutical ingredients in exchange for capping U.S. list prices on 15 high-use medicines. This agreement with the White House is expected to preserve up to $1.2 billion in annual gross profit that would otherwise be eroded by a 10% tariff, supporting the company’s 69.1% gross margin profile. By reallocating these savings into accelerated launch investments and incremental manufacturing capacity, Pfizer aims to reinforce its competitive position in vaccines and sterile injectables.

At the January 2026 World Economic Forum, CEO Albert Bourla criticized prevailing vaccine skepticism and urged a change in leadership at the U.S. Department of Health and Human Services. He highlighted a 15% reduction in federal research grants to top universities since 2020, contending that it has ceded scientific leadership to Chinese institutions, which now account for roughly 80% of global top-tier health-research rankings. Bourla recommended restoring grant levels to at least $50 billion annually and implementing regulatory reforms to accelerate immunology and oncology trials, measures he believes are essential for maintaining America’s innovation edge.